The ACCP "Excellence in Achievement" Program is pleased to recognize Michael N. Neely, MD, MSc, FCP, Chief, Div of Infectious Diseases at Children's Hosp Los Angeles and Professor of Pediatrics at the Univ of Southern California Keck School of Medicine in Los Angeles, CA. Dr. Neely has been a Member of ACCP since 2001 and became a Fellow in 2013. He served on the ACCP Board of Regents from 2013 to 2018 and was Co-chair of the Annual Meeting Program Committee in 2015 and member of the committee in 2016. Dr. Neely was also actively involved in the ACCP Finance Committee from 2016 to 2019 which he chaired from 2016 - 2018. Additionally, he has been an Annual Meeting Faculty Speaker in 2011, 2012, 2015, 2018 and 2021, On-site Poster Judge in 2014 and a Poster Presenter in 2012, 2014, 2016 and 2017. In 2020, Dr. Neely was the recipient of the Roger Jelliffe Individualized Therapy Award.
Dr. Neely’s research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, biomarker control, simulation and use of models to optimize therapy for individual patients. Although he primarily works in the therapeutic area of infectious diseases on anti-infective compounds, Dr. Neely has experience with other therapeutic areas, such as anti-neoplastic agents. He created Pmetrics, a non-parametric and parametric population modeling and simulation package for R used by investigators worldwide. Dr. Neely also created an R package for BestDose, software to optimize drug therapy for individual patients. After many years modeling anti-tuberculosis drug pharmacokinetics and pharmacodynamics with collaborators, his lab has newly acquired the equipment and expertise to conduct experiments using the hollow fiber bioreactor system to model and optimize combination antimicrobial pharmacodynamics. His lab is focusing on Mycobacterium abscessus and Staphylococcus aureus, two pathogens that cause considerable morbidity and even mortality in pediatric patients, especially those with cystic fibrosis. Dr. Neely was a member of the US Food & Drug Administration Anti-infective Drug Advisory Committee and periodically consults for the committee. He is a founding member of the Int'l Society of Pharmacometrics and an active member of the Int'l Association of Therapeutic Drug Monitoring & Clinical Toxicology. Dr. Neely has been the Principal Investigator (PI) on a National Inst of Health (NIH) K23 training grant, two R01s and is co-PI of a third R01, lead PI on a multi-center FDA U01, as well as co-investigator on other NIH grants, with continuous NIH funding since 2000. He has published more than 140 peer-reviewed articles, mentored over 50 visiting scholars, junior faculty, clinical fellows, graduate students and post-doctoral scholars and he is an invited speaker worldwide.
Dr. Neely graciously shared his thoughts on what ACCP membership means to him:
"ACCP is an inclusive organization with a mission to educate broadly in the field of clinical pharmacology. As a physician, I can attest to the critical importance of this mission and ACCP, since medical school curricula are generally lacking in clinical pharmacology training and physicians largely do not understand how to prescribe drugs beyond the blunt “one-size fits all” paradigm. ACCP fills this knowledge gap in a vital and enduring way. As my own career progresses to mentoring the next generations, I value highly ACCP’s ongoing commitment to delivering a diverse and high-quality suite of educational activities in print, online and in conferences. I am proud of my contributions to the society but even more proud to be associated with such teachers, scientists, clinicians and thought leaders. Among so many excellent peers, I am humbled and honored by this Excellence in Achievement Award!"
Congratulations, Dr. Neely, on being recognized for your outstanding achievements and contributions to ACCP!